文献速递青光眼

玻璃体腔注射贝伐珠单抗在12个月时改善小梁切除术存活:小梁切除术中贝伐珠单抗研究——一项随机临床试验

Intravitreal bevacizumab improves trabeculectomy survival at 12 months: the bevacizumab in trabeculectomy study-a randomised clinical trial.
PubMed 文献 · Br J Ophthalmol · 2024-05-21

这项单中心、平行、双盲随机安慰剂对照试验纳入需行小梁切除术的进展性青光眼患者131例,随机接受术中玻璃体腔贝伐珠单抗(n=65)或安慰剂(n=66),128例完成12个月随访。12个月时贝伐珠单抗组完全成功率94% vs 安慰剂组83%(p=0.015),合格成功率98% vs 90%(p=0.033)。

要点

  • 术中单次玻璃体腔贝伐珠单抗联合MMC小梁切除术在12个月时完全成功率和合格成功率均高于安慰剂。
  • 贝伐珠单抗组在6个月和12个月需要局部降眼压药物的比例更低,1个月需要滤过泡针刺的比例更低。
  • 贝伐珠单抗组1个月时滤过泡更大且血管炎症更少。

核心结论

  • 在小梁切除术联合MMC术中给予单次玻璃体腔贝伐珠单抗,12个月时手术成功率改善。
  • 贝伐珠单抗与达到目标眼压所需额外药物或进一步手术的需求显著减少相关。
  • 贝伐珠单抗还与滤过泡更大、炎症更少及后续干预更少相关。

研究设计与样本

  • 单中心、平行、双盲随机安慰剂对照试验,招募因进展性青光眼需行小梁切除术的患者。
  • 131例患者随机分为贝伐珠单抗组(n=65)或安慰剂组(n=66),128例完成12个月随访(98%)。

主要发现

  • 12个月时贝伐珠单抗组完全成功率94% vs 安慰剂组83%(p=0.015)。
  • 12个月时贝伐珠单抗组合格成功率98% vs 安慰剂组90%(p=0.033)。
  • 安慰剂组在6个月(p=0.045)和12个月(p=0.045)需要局部治疗的比例更高。
  • 安慰剂组在1个月需要滤过泡针刺的比例更高(p=0.035)。
  • 贝伐珠单抗组1个月时滤过泡更大(p<0.001)且血管炎症更少(p<0.0001)。

关键数值与推荐

  • 完全成功定义为眼压低于预设目标眼压且无需局部降眼压药物。
  • 合格成功定义为需要局部药物以达到预设目标眼压阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To evaluate the effect of an intraoperative dose of intravitreal bevacizumab (Avastin) on surgical success following trabeculectomy with mitomycin-C (MMC) over 12 months. METHODS: A single centre, parallel, double-blinded randomised, placebo-controlled trial recruiting patients requiring trabeculectomy for progressing glaucoma. Patients were randomised to intravitreal bevacizumab or placebo. MAIN OUTCOME MEASURE: The primary outcome of treatment success was defined by 'complete success' when intraocular pressure (IOP) remained less than a predefined target IOP without the requirement of topical medication, or 'qualified success' where topical medication was required to meet the predefined target IOP threshold. Secondary outcomes included the need for subsequent IOP-lowering interventions, and structural parameters associated with bleb function. RESULTS: From 131 patients randomised to bevacizumab (n=65) or placebo (n=66), 128 patients completed 12 months of follow-up (98%). At 12 months, success rates were higher in the bevacizumab group (complete success: 94% vs 83%; p=0.015; qualified success: 98% vs 90%; p=0.033). Within the placebo group, the requirement for topical therapy was higher at 6 months (p=0.045) and 12 months (p=0.045), and the requirement for bleb needling was higher at 1 month (p=0.035). Blebs within the bevacizumab group were larger at 1 month (p<0.001) and demonstrated less vessel inflammation (p<0.0001). CONCLUSION: Bevacizumab given as a single intravitreal dose during trabeculectomy with MMC resulted in improved surgical success as 12 months. Furthermore, bevacizumab was associated with a significant reduction in the need for additional medication or further surgery to achieve target IOP. Bevacizumab was also associated with larger blebs that were less inflamed and required fewer subsequent interventions. TRIAL REGISTRATION NUMBER: ACTRN12614000375651.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Landers JA, Mullany S, Craig JE, et al. Intravitreal bevacizumab improves trabeculectomy survival at 12 months: the bevacizumab in trabeculectomy study-a randomised clinical trial. Br J Ophthalmol. 2024. PMID: 37541768. doi:10.1136/bjo-2023-323526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。